Governance

The governance of the IMVACC MAS is constituted of :

– The Steering Committee

– The Scientific Committee

– Administrative coordinator:

Davide Mercuri

Davide Mercuri is the Program Coordinator of IMVACC since its inception.  He joined the Centre Hospitalier Universitaire Vaudois (CHUV) in May 2013 and serves the role of Grant Administrator for the Division of Immunology and Allergy (IAL) and the Swiss Vaccine Research Institute (SVRI). His main tasks consist in contributing to the financial management of the different research grants and the management of all administrative issues at the IAL and SVRI.

Davide Mercuri earned a commercial diploma and in 2012 and obtained a Federal Diploma of Higher Education as HR specialist.  During his career, he worked in positions as HR Specialist at the University of Lausanne and Figeas SA, a private health insurance company, which gave him a wealth of experience in HR management both in an academic and private environments.  Davide Mercuri speaks fluently in French, Italian and English.

Swiss Vaccine Research Institute (SVRI) and Division of Immunology & Allergy, Department of Medicine, CHUV, Lausanne

Tel: +4121 314 1872

The Steering committee is responsible for :

  • Development or modification of the IMVACC
    MAS bylaws and formal aspects of the
    curriculum.
  • Approval or amendment of the budget.
  • Admission of candidates to the IMVACC MAS,.
  • Decision to start training, depending on the
    number of candidates.
  • Proposals of granting the MAS title based on the proposal of the Scientific Committee.
  • Appointment of the program coordinator.
Steering committee:
Prof. F. Candotti

  • President of the Scientific committee
  • IMVACC program coordinator

After training in Medicine, Pediatrics, and Pediatric Allergy and Immunology at the Italian Universities of Brescia and Pavia, Prof. Candotti was granted a NIH Postdoctoral Fellowship in the laboratory of Dr. Michael Blaese at NCI and NHGRI before joining the Department of Pediatrics of the University of Brescia as an Assistant Professor in 1996 and eventually accepting a position at NHGRI that led to tenure at that institution in 2004. Ten years later, Prof. Candotti moved back to Europe to join the Division of Immunology and Allergy of the university Hospital of Lausanne in Switzerland, where he is Associate Professor of Medicine and Director of the Vaccine and Immunotherapy Center.
Throughout his career, Prof. Candotti focused on the study of the molecular basis of disorders of the immune system and the development gene therapy strategies for this heterogeneous group of diseases. He contributed to the discovery of JAK3-deficiency and AK2-deficiency as causes of SCID and performed extensive pre-clinical studies in the murine model supporting the feasibility of gene therapy for X-linked SCID and the Wiskott-Aldrich syndrome. From 2001 until 2014, Prof. Candotti co-led a series of gene therapy clinical trials for ADA-deficient SCID patients that studied the efficacy of different retroviral gene transfer vectors in humans.
Prof. Candotti has authored more than 110 peer-reviewed publications and numerous reviews and book chapters in the fields of immunodeficiency and gene therapy and is currently a member of the Editorial Board of the Journal of Clinical Immunology.

Dr. Pascale Dalla Piazza

  • Representative of UNIL-EPFL Continuing Education Foundation

Dr. Pascale Dalla Piazza, Scientific officer at the UNIL-EPFL Continuing Education Foundation

University of Lausanne (UNIL) and Swiss Technology Institute Lausanne (EPFL)

Prof. Nicolas Fasel

  • Representative of the Dean’s Office

Prof. Nicolas Fasel is full professor at the Faculty of Biology and Medicine at the University of Lausanne. After studying biology at the University of Fribourg (Switzerland) and obtaining a doctoral degree at the Swiss Institute for Experimental Cancer Research working on mouse mammary tumor virus, he took up a post-doctoral position at the University of California Los Angeles working on immunoglobulin gene regulation. On his return to Switzerland, he studied post-translational modifications of cell surface antigens. As an independant researcher of the Dr. Max Cloëtta Research Foundation, he had the opportunity to establish his own group investigating the molecular and cellular biology of protozoan parasites. His more recent research focuses on the host-pathogen interaction and the impact of co-infections. Furthermore, since 2011 he is the general secretary for the Institute of Rhematology Reserach. From 2003 to 2016, he directed the Department of Biochemistry of the Faculty and since August 2015 he is the Vice-Dean for Research and Innovation of the Faculty of Biology and Medicine.

Prof. J.-P. Kraehenbuhl

  • Health Sciences eTraining (HSeT) Foundation representative

Jean-Pierre Kraehenbuhl, MD, is the Chief Executive Officer of the Health Sciences eTraining (HSeT) Foundation. He is emeritus Professor at the University of Lausanne and Consultant at the Division of Immunology & Allergy of the University Hospital (CHUV), Lausanne, Switzerland. His field of expertise is mucosal immunology and vaccinology. He is a member of EMBO and the scientific co-founder of Oravax, now Acambis Ltd.
Jean-Pierre Kraehenbuhl received an M.D. from the University of Lausanne, Switzerland in 1967 and a PhD in 1973. He completed a postdoctoral fellowship with George Palade at the Rockefeller University and subsequently became an assistant professor at Yale University School of Medicine. In 1975, he returned to the Institute of Biochemistry at the University of Lausanne, where he became a full professor in 1984. He joined the Swiss Institute of Cancer Research (ISREC) as a senior staff member, working on epithelial-cell membrane trafficking, mucosal immunity and mucosal vaccine design.

Prof. G. Pantaleo

  • Academic Director
  • SVRI representative
  • CHUV representative
  • Representative of the Faculty of Biology & Medicine Lausanne University 

Giuseppe Pantaleo, M.D., Professor of medicine, is Chief of the Division of Immunology and Allergy. He is also Chief of the Laboratory of AIDS Immunopathogenesis at the Centre Hospitalier Universitaire Vaudois (CHUV), University of Lausanne, Switzerland. During the past ten years, Professor Pantaleo’s research has been focused on the delineation of the immunopathogenesis of HIV infection. His research activities have been focused on human T cell cloning, human T cell phenotypic and functional analysis, T cell activation, differentiation and memory, immunopathogenesis of HIV infection, HIV distribution in different anatomic compartments, antiretroviral therapy, immune reconstitution after antiretroviral therapy, immune-based therapeutic strategies and vaccines.

Professor Pantaleo is author and co-author of about 270 publications in international scientific journals.

Scientific committee:
Prof. F. Candotti

  • President
  • Program coordinator

After training in Medicine, Pediatrics, and Pediatric Allergy and Immunology at the Italian Universities of Brescia and Pavia, Prof. Candotti was granted a NIH Postdoctoral Fellowship in the laboratory of Dr. Michael Blaese at NCI and NHGRI before joining the Department of Pediatrics of the University of Brescia as an Assistant Professor in 1996 and eventually accepting a position at NHGRI that led to tenure at that institution in 2004. Ten years later, Prof. Candotti moved back to Europe to join the Division of Immunology and Allergy of the university Hospital of Lausanne in Switzerland, where he is Associate Professor of Medicine and Director of the Vaccine and Immunotherapy Center.
Throughout his career, Prof. Candotti focused on the study of the molecular basis of disorders of the immune system and the development gene therapy strategies for this heterogeneous group of diseases. He contributed to the discovery of JAK3-deficiency and AK2-deficiency as causes of SCID and performed extensive pre-clinical studies in the murine model supporting the feasibility of gene therapy for X-linked SCID and the Wiskott-Aldrich syndrome. From 2001 until 2014, Prof. Candotti co-led a series of gene therapy clinical trials for ADA-deficient SCID patients that studied the efficacy of different retroviral gene transfer vectors in humans.
Prof. Candotti has authored more than 110 peer-reviewed publications and numerous reviews and book chapters in the fields of immunodeficiency and gene therapy and is currently a member of the Editorial Board of the Journal of Clinical Immunology.

Dr. Cecilia Graziosi

Chef d’Unité de Recherche at the Laboratory of AIDS Immunopathogenesis, CHUV, Lausanne since 1996.

Italian by birth, spent most of her life in US and Switzerland. Postdoctoral studies at Yale University, Biology Department. Visiting scientist at the National Institute of Allergy and Infectious Diseases (NIAID), NIH. Executive MBA in Management of Technology (MoT), under the joined sponsorship of EPFL and HEC – UNIL in Lausanne. Speaks fluent Italian, English, French, Spanish, has a basic grasp of German and is currently learning Mandarin Chinese (HSK2).

Specialties:

Research:
HIV env sequence analysis, gp120 glycosylation, V4 intra-host variability, HIV immune escape, HIV antisense protein.
Light microscopy, in situ hybridization, RNA in vitro transcription, DNA amplification, molecular cloning, sequencing, cell culture, recombinant DNA technologies, handling of infectious materials.

Management:
Business development, Strategic thinking and planning, Training, Mentoring.

Prof. I. Knezevic

  • Professors, Teachers, Professionals experts

Dr Ivana Knezevic is Scientist in Technologies, Standards and Norms Team, and Group Lead of Norms and Standards for Biologicals in the Department of Essential Medicines and Health Products (EMP) in the World Health Organization (WHO), Switzerland.

Dr Ivana Knezevic has 22 years of professional experience in standardization, scientific and regulatory overview of biologicals. She joined WHO Biological Standardization Programme in September 2000. Since 2006, she has been leading the team for standardization of vaccines and some biological therapeutics in WHO Headquarters. Main aspects of the work include development and establishment of WHO International Standards as well as the assistance to regulators, manufacturers and other users of these standards.

In the area of biotherapeutics, she coordinated the development of WHO’s Guidelines on evaluation of Similar Biotherapeutic Products (SBPs), and organized a series of workshops to facilitate the implementation of guiding principles for evaluation of biotherapeutic products into regulatory and manufacturers’ practices.

Prof. J.-P. Kraehenbuhl

Jean-Pierre Kraehenbuhl, MD, is the Chief Executive Officer of the Health Sciences eTraining (HSeT) Foundation. He is emeritus Professor at the University of Lausanne and Consultant at the Division of Immunology & Allergy of the University Hospital (CHUV), Lausanne, Switzerland. His field of expertise is mucosal immunology and vaccinology. He is a member of EMBO and the scientific co-founder of Oravax, now Acambis Ltd.
Jean-Pierre Kraehenbuhl received an M.D. from the University of Lausanne, Switzerland in 1967 and a PhD in 1973. He completed a postdoctoral fellowship with George Palade at the Rockefeller University and subsequently became an assistant professor at Yale University School of Medicine. In 1975, he returned to the Institute of Biochemistry at the University of Lausanne, where he became a full professor in 1984. He joined the Swiss Institute of Cancer Research (ISREC) as a senior staff member, working on epithelial-cell membrane trafficking, mucosal immunity and mucosal vaccine design.

Dr. C. Meric

Claude MERIC received a PhD in molecular virology from the University of Geneva (Switzerland) and was a post-doctoral fellow (researcher) at Columbia University (New York City, USA). Then he joined Institut Mérieux (currently Sanofi Pasteur) in Lyon (France), where he worked for 24 years in R&D, mainly as a leader of various vaccine development projects including the Japanese encephalitis vaccine IMOJEV<sup>&reg;</sup>. From 2013 to 2018, he was a scientific expert in vaccine development at the the Swiss Vaccine Research Institute (SVRI) and Service of Immunology and Allergyof the Lausanne University Hospital (CHUV) in Switzerland and worked for the development of the International Master in Vaccinology (IMVACC). He is now contributing to IMVACC as a free-lance consultant.

  e-mail: claude.meric@hset.org

  Phone: +41 (0) 79 556 04 49

Prof. M. Perreau

Matthieu Perreau is a senior immunologist at the Department of Immunology and Allergy, Lausanne University Hospital, in Switzerland. He received his undergraduate degree at Nottingham Trent University in Microbiology and Biochemistry and then completed his Master’s in Haematology at the University of Denis Diderot in Paris. He subsequently joined Dr Eric Kremer’s laboratory at Montpellier II University, France, to obtain his PhD during which he focused on the interactions between viral vectors and the human immune system. In 2006, Dr Perreau joined Professor Giuseppe Pantaleo’s laboratory in Lausanne University Hospital, Switzerland, and investigated several projects in basic and applied immunology focusing on the evaluation of HIV-1 vaccine
immunogenicity and on the delineation of HIV-1 immunopathogenesis. His research has been acknowledged in several publications including Journal of Virology, Journal of Experimental Medicine and Nature Medicine

The Scientific Committee’s competencies are :

  • Design of the curriculum and Implementation of the training modules.
  • Selection of candidates and their recommendation to the Steering Committee.
  • Proposals of granting diploma equivalences for decision of the Steering Committee.
  • Proposal of granting the MAS title for decision by the Steering Committee.
  • Proposal of eliminating students for decision by the Steering Committee.
  • Validation of the internship of the participants and validation of the master’s thesis topic of the participants.